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Cancer is a major public health problem in the world. There is still a long way to go before we can manage cancer as a chronic disease or cure cancer. And now, cancer immunotherapy, a strategy that harnesses the human immune system to fight against cancer is paving the path to curing it.
Activating the immune system for therapeutic benefit in cancer has become a goal in immunology and oncology. Coley's toxin (a mixture of heatkilled bacteria) has been recognized as the first cancer immunotherapy. Since then various cancer immunotherapeutic methods have been explored and evaluated. After decades of disappointment, the tide has finally changed due to the success of recent proofof-concept clinical trials. To date, at least two different techniques show signs of helping some cancer patients. One involves immune-checkpoint blockade antibodies (e.g. by antibodies that block PD-1, PD-L1, or CTLA4) that release a brake on T cells, giving them the power to capture tumors. The other involves genetically modifying an individual›s T cells outside the body (e.g. tumor antigen-specific TCRs or chimeric antigenreceptor (CAR) gene-transduced blood T cells) to enable them to target cancer, and then reinfusing them, so that they can kill cancer cells [1] . Hence, cancer immunotherapy was selected as Breakthrough of the Year for 2013 by Science [3] .
Although cancer immunotherapy can lead to durable outcomes, the percentage of patients who respond to this disruptive approach remains modest to date. Based on various studies on mouse tumor models, immunotherapy based on cancer-specific T cells has been considered as an attractive therapeutic strategy. However, most of the cancer vaccines using tumor antigens, dendritic cells or modified cancer cells, which are supposed to induce anti-tumor T cells to eradicate cancer cells, have failed to show significant antitumor effects in phase III trials [2] .
A central question in cancer immunology is whether recognition of tumor antigens by the immune system leads to activation (i.e., surveillance) or tolerance. The effect of traditional immunotherapy is modest, frequently due to tumor escape and resistance of multiple mechanisms [3] . Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. For example, human CIK cells labeled with gold nanorods were used for photothermal-immunological combined therapy of in vivo gastric cancer models, and maximal tumor growth inhibition was achieved. The fact highly suggests that available nanotechnology can be used for enhanced immunotherapeutic efficacy [4] . Cancer nanotechnology or cancer nanomedicine has provided a practical solution for overcoming the limitations of traditional immunotherapy. N a n o t e c h n o l o g y h a s t h e p o t e n t i a l t o revolutionize cancer theranostics. Encouragingly, some nanostructures have already been demonstrated to be applicable as a drug delivery system, and the application of nanotechnology can improve the efficacy of immunostimulatory small molecules by altering their co-localization, bio-distribution and release kinetics [5] - [7] . Extensive evidence d e m o n s t r a t e s t h a t n a n o c a r r i e r s ( i n c l u d i n g micelles, liposomes, polymer-drug conjugates, metal nanoparticles, solid lipid nanoparticles and biodegradable nanoparticles) could be used for the cellular transfer of immune effectors for active and passive nanoimmunotherapy [3] . Nanocarriers can be used to enhance cancer immunotherapy at four alternative pathways: (1) deliver cancer vaccine antigens and adjuvants to dendritic cells, (2) stimulate T cells directly as artificial antigen presenting cells, (3) concentrate immunostimulatory compounds in the immunosuppressive tumor microenvironment, and (4) deliver supportive drugs to T cells in the circulation [2] . The smart engineering of nanocarriers based on the unique features of the tumor microenvironment and extra-/intra-cellular conditions of tumor cells can greatly tip the triangle immunobalance among host, tumor and nanoparticles in favor of antitumor responses, which shows a promising prospect for nanoimmunotherapy [3] .
E m e rg i n g e v i d e n c e c o n f i r m s t h a t c a n c e r immunotherapies have started to combine with nanotechnology and thus created a novel area, that is cancer nano-immunoengineering. Cancer nanoimmunoengineering can generate adaptive and durable responses, yielding much more robust antitumor effects when they are formulated in nanoparticles or scaffolds than when they are administered as free drugs. Cancer nano-immunoengineering aims to fully use the advantages of nanoparticles and nano-effects, enhance immunotherapeutic cells' killing tumor effects, regulate immuno-network, and realize precise cancer targeted theranostics. How to promote the development of nano-immunoengineeirng and how to clarify the mechanism of interaction between immunonetworks and nanoparticles have become novel key scientific problems.
Cancer nano-immunoengineering is a promising area worthy of further consideration and deep investigation. A series of products based on cancer nano-immunoengineering will affect clinical cancer theranostics in near future. 
